SAB Biotherapeutics to take part in upcoming investor conferences
SAB Biotherapeutics, Inc. (Nasdaq: SABS) said members of its management team will participate in upcoming investor conferences.
MIAMI, Sept.
01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team w…